Tevogen Reports Q3 2025 Earnings, Highlights Capital Efficiency Amidst Industry Sustainability Challenges

Tevogen reported a Q3 2025 loss from operations of $5.7 million, a 6% reduction from the same period in 2024. The company also saw a 51% reduction in operating loss for the nine months ended September 30, 2025, compared to the same period in 2024. Tevogen highlighted its continued capital efficiency at a time when sustainability is a defining challenge for the biotechnology industry.